PL92423B1 - Isoindolino-quinoline derivs - useful as tranquillizers and anticonvulsants[FR2167217A1] - Google Patents

Isoindolino-quinoline derivs - useful as tranquillizers and anticonvulsants[FR2167217A1] Download PDF

Info

Publication number
PL92423B1
PL92423B1 PL1972175094A PL17509472A PL92423B1 PL 92423 B1 PL92423 B1 PL 92423B1 PL 1972175094 A PL1972175094 A PL 1972175094A PL 17509472 A PL17509472 A PL 17509472A PL 92423 B1 PL92423 B1 PL 92423B1
Authority
PL
Poland
Prior art keywords
carbon atoms
general formula
formula
halogen
group
Prior art date
Application number
PL1972175094A
Other languages
Polish (pl)
Original Assignee
Chrysler Francefr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chrysler Francefr filed Critical Chrysler Francefr
Publication of PL92423B1 publication Critical patent/PL92423B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • GPHYSICS
    • G03PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03GELECTROGRAPHY; ELECTROPHOTOGRAPHY; MAGNETOGRAPHY
    • G03G15/00Apparatus for electrographic processes using a charge pattern
    • G03G15/14Apparatus for electrographic processes using a charge pattern for transferring a pattern to a second base
    • G03G15/16Apparatus for electrographic processes using a charge pattern for transferring a pattern to a second base of a toner pattern, e.g. a powder pattern, e.g. magnetic transfer

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Title derivs are cpds of formula (I) (where X is halogen, 1-4C alkyl, 1-4C alkoxy, NO2 and/or H; Y is halogen, 1-4C alkyl, 1-4C alkoxy, CN, NO2 and/or H; and n is 0 or 1) and their acid addition salts. (I) in which n is 0 are obtained by reacting an alkali salt of a cpd of formula (II) with 1-chlorocarbonyl-4-methylpiperazine or by reacting a cpd of formula (II. -OH=-OCOOAr) (where Ar is opt. substituted aryl) with 1-methylpiperazine, and may be converted into (I) in which n is 1 by oxidn. [FR2167217A1]

Description

Przedmiotem wynalazku jest sposób wytwarza¬ nia nowych pochodnych izoindoliny i ich soli ad¬ dycyjnych z kwasami o ogólnym wzorze 1, w któ¬ rym X oznacza atomy lub grupy, jednakowe, lub rózne, takie jak atom wodoru i chlorowca, grupa alkilowa zawierajaca 1—4 atomów wegla, grupe alkoksylowa, której czesc alkilowa zawiera 1—4 atomów wegla i grupe nitrowa, zas Y ozinacza atomy lub grupy, jednakowe lufo rózne, takie -jak atom wodoru i chlorowca, grupe alkilowa zawie¬ rajaca 1—4 atomów wegla, grupe alkoksylowa, której czesc alkilowa zawiera 1—4 atomów we¬ gla, ,gruipe cyjanowa i grupe nitrowa.Wedlug wynalazku zwiazki o ogólnym wzorze 1 wytwarza sie dzialajac 1-metylcpiperazyna na mieszany weglan o ogólnym wzorze 2, w którym X i Y maja wyzej podane znaczenia a Ar ozinacza .grupe fenylowa, ewentualnie podstawiona grupe alkilowa zawierajaca 1—4 atomów wegla. .Reakcje prowadzi sie .zazwyczaj w rozpuszczal- iniku organicznym, takim jak aeetonitryl, w tem¬ peraturze 10—35°C.Mieszany weglan o ogólnym wzorze 2 otrzymu¬ je sie znanym sposobem dzialajac chiloromrówcza- nem o ogólnym wzorze 3, w którym Ar ma wy¬ zej podane znaczenie, na pochodna izoindoliny o ogólnym wzorze 4, w którym X i Y maja wy¬ zej okreslone znaczenie.Reakcje prowadzi sie zazwyczaj w zasadowym rozpuszczalniku organicznym, takim jak pirydy¬ na, w temperaturze ponizej 10°C.^ Pochodne izo- indoliny o wzorze ogólnym 4 wytwarza sie zna¬ nym sposobem przez redukcje czesciowa ftalimi- du o wzorze ogólnym 5, w którym Xi Y maja wy¬ zej okreslone znaczenie. Przewaznie redukcji do¬ konuje sie przy uzyciu alkalicznego borowodorku w roztworze wodnoorganicznym.Jesli rodnik ftalimiido jest podstawiony w spo¬ sób niesymetryczny, czesciowa redukcja produk¬ tu o ogólnym wzorze 5 moze prowadzic do pro¬ duktów izomerycznych, które mozna (rozdzielic metodami fizykochemicznymi, takimi jak krysta¬ lizacja frakcjonowana lulb chromatografia.Ftaliimid O' ogólnym wzorze 5 mozna otrzymac dzialajac amino-chinolina na bezwodnik ftalowy o ogólnym wzorze 6, w którym X ma wyzej okre¬ slone znaczenie.Nowe produkty o ogólnym wzorze 1 moga byc ewentualnie oczyszczone za pomoca metod fizycz¬ nych, takich jak destylacja, krystalizacja, chro¬ matografia, lub chemicznych, takich jak tworze¬ nie soli, ich krystalizacja, a nastepnie rozklad w srodowisku alkalicznym, przy czym w opera¬ cjach tych rodzaj anionu soli jest obojetny, pod warunkiem, ze jest to sól scisle okreslona i latwa do krystalizacji.Nowe produkty otrzymywane sposobem wedlug wynalazku moga byc przeksztalcone w sole addy¬ cyjne z kwasami. Sole addycyjne otrzymuje sie dzialaniem nowych zwiazków na kwasy w odpo¬ wiednich rozpuszczalnikach. Jako rozpuszczalniki organiczne stosuje sie: alkohole, ketony lub roz- 92 4233 puszczalniki chlorowane. Utworzona sól wytraca sie po ewentualnymi zatezeniu roztworu i oddzie¬ la sie ja przez filtracje lub dekantacje.Nowe produkty otrzymywane sposobem wedlug wynalazku oraz ich sole addycyjne posiadaja in¬ teresujace wlasnosci farmakologiczne. Wykazuja- one szczególna aktywnosc jako srodki uspoka¬ jajace i przeciwkonwulsyjne. Dla zwierzat (my¬ szy) sa aktywne w dawce 10—100 mg/kg przy po¬ daniu per os, zwlaszcza w nastepujacych testach: elektroterapii, wedlug 'techniki zblizonej do opi¬ sanej przez Tedeschi i j wspólprac. [J. Phanmacol, 125, 28 (1959)], drgawek wywolanych pentetrazo- lem, wedlug techniki zblizonej do opisanej przez Everetta i Richardsa [J. Phanmacol., 81; 402 T- »41fl^L^^ekitrowstrzasu; ponadmaksymalnego we- /•^ ^^aiujg'.tecl\niki|Giwinyorda i innych [J. Phasrmacol., * 106, 319 {1952)] i iodniecenie ruchowe we- | dlug techniki Courvoisiera (zaprezentowanej na l ^^J^RMn^reslfc * Lekarzy Psychiatrów i Neurologów w * *•"- ''Toucs^lw^dnjiach 8-^13.VI.1959) i Joiou (Bulletin de la Societe de Pharmacie de Lille, nr 2, styczen 1967,^. 7).Nowe zwiazki uzywa sie w medycynie badz w postaci zasad badz soli addycyjnych farmaceutycz¬ nie dopuszczalnych, tzn. nie toksycznych w stoso¬ wanych dawkach.Jako przyklady soli addycyjnych dopuszczalnych farmaceutycznie mozna przytoczyc sole kwasów mineralnych, takie jak chlorowodorki, siarczany, azotany, fosforany lub sole kwasów organicznych, takie jak octany, propioniany, bursztyniany, ben¬ zoesany, fumarany, maleindany, szczawiany, octa¬ ny teoifiiliny, salicylany, fenolotftaliniany, metyleno- ^bis-p-oksynaftoesany lub produkty podstawienia tych kwasów.Przyklad I. Do zawiesiny 20 g 2-/6-nitro-2-chi- noliloy~3-oksykarbonylofenoksyizoindolinoinu-l w 200 cm* acetoni.trylu dodano 13,6 g 1-metylopipe- razyny i mieszano w ciagu 40 godzin w tempera¬ turze okolo 20°C. Nastepnie odfittrowanp wykry¬ stalizowany produkt i przemyto go 15 om* aceto- nitirylu i 30 om* eteru izopropylowego. Po wysusze¬ niu otrzymano 18 g produktu o temperaturze top¬ nienia 210°C i zmieszano go z 250 cm* chlorku me¬ tylenu.Odfiltrowano 3 g nierozpuszczonego osadu, a otrzymany roztwór przesaczono przez 400 g silika- zelu zawartego w kolumience o srednicy 5,5 cm.Nastepnie eluowano 6000 cm* chlorku metylenu, 1000 om* mieszaniny chlorek metylenu — metanol (99:1, cz. ofoj.) i 2000 om* mieszaniny chlorek mety¬ lenu — metanol (98:2, cz. ofoj.). Wszystkie eluaty odrzucono. Dalej eluowano 2000 om* mieszaniny chlorek metylenu — metanol (98:2, cz. obj.) a otrzy¬ many roztwór odparowano do sucha pod zmniej¬ szonym cisnieniem. Pozostalosc wykrystalizowano z 70 om* dwumetytloformamidu. Otrzymano 11,1 g 3^[oksykaribonylo-/4Hmetylo-l-ipitperazynylo/]-2-/6- -nitro-i2-chinoliilo/izoiindolinonu-l o temperaturze topnienia 227°C. 2-^-nitro-2-chino izoindolinon"l otrzymano przez dodanie 0,95 g chloroimrówczanu fenylu do zawiesiny ly2 g 3-foy- 423 4 droksy-2-/6-natro-2^chinolilo/izoindolinojnu- 12 om* pirydyny, utrzymujac przy tym temperatu¬ re okolo 5°C. Po zakonczeniu dodawania miesza¬ nine reakcyjna mieszano jeszcze w ciagu 3 go- dzin w temperaturze o^olo 20°C, po czym doda¬ no 60 cm* wody. Nierozpuszczalny produkt oddzie¬ lono przez filtracje, przemyto siikcesywnie 30 om* wody, 10 cm* acetonitr^lu i 20 cm* eteru izopro¬ pylowego. Po wysuszeniu otrzymano; l& g 2-/6-ni- tro-2-chmoMlo/-3-oksykarbonylofenoksyizodndoli- nonu-1 o temperaturze ^topnienia 228—230°C. 3-hydroksy^-/6-niitro-2Hchinolilo/izoindolinon-1 o temperaturze topnienia 298°C otrzymano dzia¬ laniem borowodorku potasowego na 6-nitro-2-fta- Mmidochinoline w srodowisku wodnoimetanolowym w temperaturze okoloi 20°C. ¦ 6Hnitro-2-ftalimidochinoMne o temperaturze top¬ nienia 264°C otrzymano dzialaniem bezwodnika ftalowego na 2-amino^6-nitrochinoline w eterze dwufenylowym w temperaturze okolo 240°C. 2-airnino^-inditrochiaiOiline otrzymano metoda opi¬ sana przez H. Outhmanna [J. Prakt. Ohem., 93, 386 <1916)].Przykladu. Postepujac jak w przykladzie Ir lecz wychodzac z odpowiednich substancji wyjscio¬ wych otrzymano nastepujace produkty: — 3[oksykarfoonylo-y4-metylo-il-piperazynylo/}2-/2- ^chinolilo/iizoindolinon-l o temperaturze topnie- nia 160°C — 3[oksykarbonylo-/4-metylo-1-piperazynylo/]-2/7- -chloro-2^chinojlilo/izoindolinon-l o temperaturze topnienia 174°C, — 3[oksykaribonylo-/4-imetylo-l-piperazynylo/] -2/7- ^nitro-S-chinollilo/izoindolinon-l o temperaturze topnienia 240°C. — 3[oksykarbónylo-2-/7-metoksy-2-chmoldlo/-/4-me- tylo^l-piperazynylo/]izoindolinon-l o temperatu¬ rze topnienia 195°C.— S [oksykarbonylo-/4-(metylo^lipiperazynylo/]-2/7- Hmetyio-2Hchinoliio/ize4ndolinon-l o temperatu- . rze topnienia 162—il63°C.^ // \. (U O INzdr CL-CO-O-Ar Wzór 3 O (X)4-4 I O o Wzór 6 PLThe subject of the invention is a process for the preparation of new isoindoline derivatives and their addition salts with acids of the general formula I, in which X represents atoms or groups, identical or different, such as hydrogen and halogen, an alkyl group containing 1- 4 carbon atoms, an alkoxy group, the alkyl group of which contains 1-4 carbon atoms and a nitro group, and Y stands for identical or different atoms or groups, such as hydrogen and halogen, an alkyl group of 1-4 carbon atoms, an alkoxy group, the alkyl portion of which contains 1-4 carbon atoms, a cyano group and a nitro group. According to the invention, compounds of general formula I are prepared by treating 1-methylpiperazine on a mixed carbonate of general formula II, in which X and Y have the above and Ar is given as meaning a phenyl group, optionally substituted with an alkyl group having 1-4 carbon atoms. The reactions are usually carried out in an organic solvent, such as aeetonitrile, at a temperature of 10-35 ° C. The mixed carbonate of the general formula II is prepared in a known manner by treatment with a chloroformate of the general formula III, in which Ar is as defined above for the isoindoline derivative of formula IV, where X and Y are as defined above. The reactions are generally carried out in a basic organic solvent such as pyridine at a temperature below 10 ° C. The isoindoline derivatives of the general formula IV are prepared in a known manner by partial reduction of the phthalimide of the general formula V in which X and Y are as defined above. Usually the reduction is done with an alkaline borohydride in an organic aqueous solution. If the phthalimido radical is unsymmetrically substituted, partial reduction of the product of general formula 5 may lead to isomeric products which can be separated by physicochemical methods such as as fractionated crystallization or chromatography. Phthalimide O 'of general formula 5 can be obtained by treating the amino quinoline with phthalic anhydride of general formula VI, in which X has the meaning defined above. New products of general formula I may optionally be purified by physical methods such as distillation, crystallization, chromatography, or chemical methods such as salt formation, crystallization and subsequent decomposition in an alkaline environment, the type of salt anion being inert in these operations, provided that that it is a precisely defined salt and easy to crystallize. New products obtained by the method according to the invention can be transformed with acid addition salts. Addition salts are obtained by the action of new compounds on acids in suitable solvents. The organic solvents used are: alcohols, ketones or chlorinated solvents. The salt formed is precipitated, if the solution is concentrated, and it is separated by filtration or decantation. The new products obtained according to the invention and their addition salts have interesting pharmacological properties. They are particularly active as sedatives and anti-convulsants. For animals (mice) they are active at a dose of 10-100 mg / kg per person, especially in the following tests: electrotherapy, according to a technique similar to that described by Tedeschi and her collaboration. [J. Phanmacol, 125, 28 (1959)], pentetrazol-induced convulsions, according to a technique similar to that described by Everett and Richards [J. Phanmacol, 81; 402 T- »41fl ^ L ^^ ecitro-shock; over-maximal we- / • ^ ^^ aiujg'.tecl \ niki | Giwinyord and others [J. Phasrmacol., * 106, 319 {1952)] and motor stimulation in- | Debt of Courvoisier's technique (presented on l ^^ J ^ RMn ^ reslfc * Psychiatrists and Neurologists in * * • "- '' Toucs ^ l in ^ dnjiach 8- ^ 13.VI.1959) and Joiou (Bulletin de la Societe de Pharmacie de Lille, No. 2, Jan. 1967, ^. 7). The new compounds are used in medicine either in the form of bases or addition salts that are pharmaceutically acceptable, i.e., non-toxic in the doses used. Examples of pharmaceutically acceptable addition salts are salts of mineral acids, such as hydrochlorides, sulfates, nitrates, phosphates, or organic acid salts, such as acetates, propionates, succinates, benzoates, fumarates, maleindanes, oxalates, theoifiyl acetates, salicylates, phenolphthalates, methylene bis- p-oxynaphthoates or their substitution products Example I. To a suspension of 20 g of 2- (6-nitro-2-quinolyl ~ 3-oxycarbonylphenoxyisoindolin-1-1 in 200 cm * acetonitrile) 13.6 g of 1-methylpipe- times and stirred for 40 hours at a temperature of about 20 ° C. Sat. the precipitated crystallized product is melted and washed with 15 ml of acetonitrile and 30 ml of isopropyl ether. After drying, 18 g of the product having a melting point of 210 ° C. are obtained and mixed with 250 ml of methylene chloride. 3 g of undissolved solids are filtered off, and the obtained solution is filtered through 400 g of silica gel contained in a column of diameter 5 5 cm. Subsequently, elution was carried out with 6,000 cc of methylene chloride, 1,000 ml of a mixture of methylene chloride-methanol (99: 1, diluted) and 2000 of a mixture of methylene chloride-methanol (98: 2, diluted ). All eluates were discarded. A further 2,000 ml of methylene chloride-methanol (98: 2, v / v) mixture was eluted and the resulting solution was evaporated to dryness in vacuo. The residue was crystallized from 70 ohm * dimethylformamide. 11.1 g of 3 [oxycaribonyl- (4H-methyl-1-ipitperazinyl] -2- (6-nitro-i-2-quinolyl) isoindolinone-1 with a melting point of 227 ° C were obtained. 2 - Nitro-2-quino isoindolinone "1 was obtained by adding 0.95 g of phenyl chloroformate to a suspension of 2 g of 3-foy-423 4-dioxy-2- (6-natro-2-quinolyl) isoindolinone-12 m * pyridine while maintaining the temperature at about 5 ° C. After the addition was complete, the reaction mixture was stirred for a further 3 hours at a temperature of about 20 ° C., then 60 cm.sup.3 of water was added. It was poured by filtration, washed successively with 30 ml of water, 10 cm3 of acetonitrile and 20 cm3 of isopropyl ether. Drying gave 1 g of 2- (6-nitro-2-hops) -3-oxycarbonylphenoxyisodndol. nonu-1, mp 228-230 ° C. 3-hydroxy (6-nitro-2H-quinolyl) isoindolinone-1, mp 298 ° C, was obtained by treatment with potassium borohydride on 6-nitro-2-phta-M-quinoline in a water-methanol environment at a temperature of about 20 ° C. 6H-nitro-2-phthalimidoquinoline with a melting point of 264 ° C was obtained by the action of phthalic anhydride on 2-amino-6-nitroquinoline in ether with diphenyl at about 240 ° C. 2-airnino-inditrochiline was obtained by the method described by H. Outhmann [J. Practice. Ohem., 93, 386 <1916)]. Following the example of Ir, but starting from the appropriate starting materials, the following products were obtained: - 3 [oxycarfoonyl-γ-methyl-yl-piperazinyl)} 2- (2-quinolyl) isoindolinone-1 with a melting point of 160 ° C. - 3 [oxycarbonyl- (4-methyl-1-piperazinyl) - 2 (7- chloro-2-quinoylyl) isoindolin-1, m.p. 174 ° C, - 3 [oxycaribonyl- (4-imethyl-1-piperazinyl) [2] -2 [7-] nitro-S-quinolyl) isoindolinone-1, m.p. 240 ° C. - 3 [oxycarbonyl-2- (7-methoxy-2-chmoldlo) - (4-methyl-1-piperazinyl)] isoindolinone-1, m.p. 195 ° C. - S [oxycarbonyl- (4- ( Methyl-Lipiperazinyl] - 2 (7- H-Methyl-2H-quinolium) -Ize4ndolin-1 with a melting point of 162-il63 ° C ^ // \. (UO INzdr CL-CO-O-Ar Formula 3 O (X) 4-4 IO o Formula 6 PL

Claims (1)

1. Zastrzezenie patentowe Sposób wytwarzania pochodnej izoindoliny o og61nym wzorze 1, w którym X oznacza atomy lufo grupy, jednakowe lufo rózne, takie jak atom ^ wodoru i chlorowca, grupe alkilowa zawierajaca 1—4 atomów wegla, grupe alkoksylowa, której czesc alkilowa zawiera 1—4 atomów wegla, gru¬ pe nitrowa, zas Y oznacza atomy lufo grupy, jed¬ nakowe lufo rózne, takie jak atom wodoru i chlo- ^ rowca, grupe alkilowa, zawierajaca 1—4 atomów wegla, grupe alkoksylowa, której czesc alkilowa zawiera 1—4 atoimów wegla, grupe cyjanowa i ni¬ trowa, oraz ich soli addycyjnych z kwasami, zna¬ mienny tym, ze prowadzi sie reakcje 1-unetylopi- w perazyny i mieszanym weglanem o ogólnym wzo¬ rze 2, w którym X i Y maja wyzej podane znacze¬ nie, a Ar oznacza rodnik fenylowy, ewentualnie podstawiony, nastepnie ewentualnie przeksztalca sie otrzymany produkt w sól addycyjna z kwa- 66 sem*92 423 O (X)ii i ,N (Y)4 Ó-C0--NCIM-CH3 iMzór ii O-CO-O-Ar Wzór 2 O W* PLClaim 1. A process for the preparation of an isoindoline derivative of the general formula I, in which X represents or groups, the same or different groups, such as hydrogen and halogen, an alkyl group containing 1-4 carbon atoms, an alkoxy group whose alkyl part contains 1 - 4 carbon atoms, nitro group, and Y represents or group atoms, alike different ones, such as hydrogen and halogen, an alkyl group having 1-4 carbon atoms, an alkoxy group whose alkyl part contains 1-4 carbon atoms, cyano and nitrous groups, and their acid addition salts, characterized in that the reactions of 1-unethylpyrin perazine and mixed carbonate of general formula 2 are carried out, wherein X and Y have the meanings given above, and Ar is a phenyl radical, optionally substituted, then optionally the resulting product is converted into an acid addition salt of 92 423 O (X) ii i, N (Y) 4? -C0-- NCIM-CH3 iMzór ii O-CO-O-Ar Formula 2 OW * PL
PL1972175094A 1972-01-10 1972-12-28 Isoindolino-quinoline derivs - useful as tranquillizers and anticonvulsants[FR2167217A1] PL92423B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7200650A FR2167217A1 (en) 1972-01-10 1972-01-10 Isoindolino-quinoline derivs - useful as tranquillizers and anticonvulsants

Publications (1)

Publication Number Publication Date
PL92423B1 true PL92423B1 (en) 1977-04-30

Family

ID=9091655

Family Applications (2)

Application Number Title Priority Date Filing Date
PL1972175094A PL92423B1 (en) 1972-01-10 1972-12-28 Isoindolino-quinoline derivs - useful as tranquillizers and anticonvulsants[FR2167217A1]
PL1972159839A PL89131B1 (en) 1972-01-10 1972-12-28 Isoindolino-quinoline derivs - useful as tranquillizers and anticonvulsants[FR2167217A1]

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL1972159839A PL89131B1 (en) 1972-01-10 1972-12-28 Isoindolino-quinoline derivs - useful as tranquillizers and anticonvulsants[FR2167217A1]

Country Status (10)

Country Link
JP (1) JPS5622780A (en)
AR (1) AR202800A1 (en)
AU (1) AU468083B2 (en)
CS (2) CS181748B2 (en)
ES (2) ES410490A1 (en)
FR (1) FR2167217A1 (en)
PL (2) PL92423B1 (en)
SU (2) SU488409A3 (en)
YU (2) YU35766B (en)
ZA (1) ZA73118B (en)

Also Published As

Publication number Publication date
ZA73118B (en) 1973-09-26
AU468083B2 (en) 1975-12-18
FR2167217B1 (en) 1975-06-13
JPS5653310B2 (en) 1981-12-17
YU35766B (en) 1981-06-30
FR2167217A1 (en) 1973-08-24
SU488409A3 (en) 1975-10-15
JPS5622780A (en) 1981-03-03
YU184773A (en) 1980-10-31
YU187473A (en) 1980-10-31
CS181717B2 (en) 1978-03-31
ES410490A1 (en) 1975-12-01
CS181748B2 (en) 1978-03-31
PL89131B1 (en) 1976-10-30
AU5087673A (en) 1974-07-11
ES410489A1 (en) 1975-12-01
SU499805A3 (en) 1976-01-15
AR202800A1 (en) 1975-07-24

Similar Documents

Publication Publication Date Title
NO136843B (en) ANALOGICAL PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE DERIVATIVES OF 5,6-DIHYDRO-PYRROLO (3,4-B) PYRAZINE.
DE2760287C2 (en)
JPS6345261A (en) Novel quinolone derivative, ester and salt thereof
FI65623C (en) EXAMINATION OF ANTIBIOTICS ACTIVE (6R 7R) -3-CARBAMOYLOXIMETHYL-7- (2- (FUR-2-YL) -2-METHOXIMINOACETAMIDO) -CEF-3-EM-4-CARBOXYL SYRICATE
US3714149A (en) Pyridobenzodiazepinones
DK141511B (en) Analogous process for the preparation of derivatives of wind blastin, leurosidine or leurocristine.
JP3175164B2 (en) Heterotricyclic derivatives, process for their preparation and pharmaceutical compositions containing them
PL85030B1 (en)
EP0544166A2 (en) Cephalosporinderivatives
EP0163190A2 (en) Beta-lactam antibiotics, process for their preparation and their use as medicaments on growth stimulators in animal-raising or as anti-oxidants
EP0144032B1 (en) Cephalosporins and process for their preparation
PL92423B1 (en) Isoindolino-quinoline derivs - useful as tranquillizers and anticonvulsants[FR2167217A1]
JPS60126284A (en) Pyridonecarboxylic acid derivative and salt thereof
US6906096B2 (en) 4,7-Disubstituted indoles and methods of making
JPS61126082A (en) Aminopyrrolidone derivative, its ester and its salt
Scott et al. Studies in the Pyrazole Series. I. Halogenation of the 1-Guanylpyrazoles1
NO136840B (en) ANALOGICAL PROCEDURE FOR THE PREPARATION OF NEW, THERAPEUTICALLY ACTIVE DERIVATIVES OF ISOINDOLIN.
OA12968A (en) Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof.
FI70218C (en) FRAME FOR THE PREPARATION OF THERAPEUTIC THERAPEUTIC 3-SUBSTITUTE TETRAHYDROPYRROLO / 1,2-A / PYRIMIDINER
JPS6089480A (en) Pyridonecarboxylic acid derivative
US3546220A (en) 2,3-dihydro-1h-pyrido-(2,3-b)(1,4)thiazines
SE452622B (en) N- (VINBLASTINOYL-23) DERIVATIVES OF AMINO ACIDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS
DE3853311T2 (en) Thiadiazolylacetamide cephem derivatives.
JPS61137885A (en) 1,8-naphthylidine derivative, its ester and salt
EP0044238A1 (en) Cephalosporin sulfoxides, process for their preparation and pharmaceutical compositions containing them